H.C. Wainwright raised the firm’s price target on ANI Pharmaceuticals to $87 from $83 and keeps a Buy rating on the shares post the Q1 report. The company reported its eighth straight top and bottom-line beat, and reiterated guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals sees 2024 adjusted EPS $4.26-$4.67, consensus $4.48
- ANI Pharmaceuticals reports Q1 adjusted EPS $1.21, consensus $1.00
- ANIP Upcoming Earnings Report: What to Expect?
- ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences
- ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET